All studies
RecruitingOBSERVATIONAL

MPN Childhood Registry

This study is creating a special collection of information, called a registry, for children and teenagers in Germany who have rare blood conditions known as myeloproliferative neoplasms (MPNs). MPNs can cause the body to make too many blood cells, leading to symptoms like headaches or blood clots. These conditions are much more common in older adults, so very little is known about how they affect young people. Doctors are currently using guidelines meant for adults, which might not be the best for children. This registry will help researchers understand the specific features, treatments, and outcomes of MPNs in children and teenagers. The goal is to develop better ways to diagnose and treat young patients, making sure their unique needs are met and improving their long-term health.

At a glance

Status
Recruiting
Sponsor
University of Erlangen-Nürnberg Medical School
Enrolment target
500
Start
01 Jan 2023
Estimated completion
31 Dec 2037

What is this study about?

Myeloproliferative neoplasms, or MPNs for short, are a group of conditions where the body's blood-making factories in the bone marrow don't quite work right. This can lead to your body producing too many of certain mature blood cells, like red blood cells or platelets. When there are too many of these cells, it can sometimes cause health problems. For example, you might experience headaches, or have issues with blood clotting, which can lead to blocked blood vessels or even bleeding. In some rare cases, over a long time, the bone marrow can change, or a more serious type of blood cancer called acute leukemia can develop.

While MPNs are mostly found in older adults, they are extremely rare in children and teenagers. Because of this, doctors don't have much information about how these conditions affect young people specifically. We don't fully understand their unique characteristics, the best ways to treat them, or what the long-term outlook might be. Currently, doctors often rely on treatment guidelines that were developed for adults, which might not be perfectly suited for growing bodies.

That's why this study is so important. It's setting up a nationwide registry in Germany. Think of a registry as a secure, organised collection of information from many children and teenagers with MPNs. By carefully gathering details about each young person's condition, their symptoms, how they are treated, and how they progress, researchers hope to gain a much clearer picture of MPNs in childhood. This will help them understand the disease better in young people compared to adults, ultimately leading to improved diagnosis and more tailored, effective treatments for children and teenagers.

Key takeaways

  • This study collects information on rare blood conditions (MPNs) in children.
  • It aims to understand MPNs better in young people, as most research is on adults.
  • Participation involves sharing existing medical records, not new treatments.
  • The goal is to improve future diagnosis and treatment for children with MPNs.
  • Information is kept confidential, and you can withdraw at any time.

Who may be eligible?

This study is looking for children and teenagers who have been newly diagnosed with specific types of MPNs. These include conditions called polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis (PMF), or a condition known as hypereosinophilic syndrome (HES).

To join, a child or teenager must be under 18 years old at the time they were diagnosed (up to 17 years and 365 days). They also need to be receiving their care at one of the hospitals or clinics that is taking part in this registry. Finally, their parent or legal guardian will need to give their written permission for the child's information to be included in the study.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Has your child been diagnosed with PV, ET, PMF, or HES?
  2. Is your child under 18 years old?
  3. Is your child being treated at a hospital taking part in this study?
  4. Are you, as a parent or guardian, willing to give written permission?
Answer every question to see your result.

What does participation involve?

This study is mainly about collecting information, not giving a specific treatment. If you decide to take part, your doctor will share information about your child's diagnosis, health, and how their condition is being managed with the study's researchers. This includes details from their medical records, such as test results and treatment plans. There will be no new medicines or extra hospital visits just for this study; everything will be part of your child's usual care. The study aims to follow how children with MPNs progress over time, so information will be collected as part of their ongoing treatment. The total duration for each child's participation will depend on how long they continue to be monitored for their MPN by their healthcare team.

Potential risks and benefits

Taking part in this registry largely involves sharing existing medical information, so there are very few direct risks. Your child will not be given new treatments or have extra tests as part of the study. All shared information is kept confidential. The potential benefit is that by carefully collecting data from many children, this study will help doctors learn more about rare MPNs in young people. This improved understanding could lead to better diagnoses and treatments for children with these conditions in the future. You always have the right to withdraw your child's information from the registry at any time without affecting their medical care.

Locations (1)

  • Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany
    Verified postcode
    Erlangen, Germany· Recruiting

Common questions

What is an MPN?

MPN stands for Myeloproliferative Neoplasm. It's a rare blood condition where your body makes too many blood cells.

Why is this study only for children?

MPNs are very rare in children, so doctors need more information specific to young people to understand and treat these conditions better.

Will my child get new medicine for this study?

No, this study is about collecting information from your child's usual care, not giving new medicines or treatments.

Is my child's information safe?

Yes, all personal and medical information collected for the study will be kept private and secure.

Can we stop participating later?

Yes, you can decide to withdraw your child's information from the study at any time, and it won't affect their medical care.

How to find out more

Axel Karow, PD Dr. med.

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "MPN Childhood Registry…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.